Dopamine agonists in prevention of ovarian hyperstimulation syndrome
| العنوان: | Dopamine agonists in prevention of ovarian hyperstimulation syndrome |
|---|---|
| المؤلفون: | Patrik Stanić, Slavko Orešković, Lidija Beketić-Orešković, Miro Kasum, Davor Ježek, Hrvoje Vrcic, Marijeta Pekez |
| المصدر: | Gynecological Endocrinology. 30:845-849 |
| بيانات النشر: | Informa UK Limited, 2014. |
| سنة النشر: | 2014 |
| مصطلحات موضوعية: | medicine.medical_specialty, Cabergoline, Dopamine agonist, ovarian hyperstimulation syndrome, prevention, Endocrinology, Diabetes and Metabolism, Ovarian hyperstimulation syndrome, Placebo, Ovarian Hyperstimulation Syndrome, Endocrinology, Ovulation Induction, Dopamine, Internal medicine, medicine, Humans, Ergolines, Bromocriptine, business.industry, Quinagolide, Obstetrics and Gynecology, medicine.disease, Regimen, Dopamine Agonists, Aminoquinolines, Female, business, medicine.drug |
| الوصف: | The aim of this review is to analyze the efficacy of different dopamine agonists in the prevention of ovarian hyperstimulation syndrome (OHSS). Cabergoline, quinagolide and bromocriptine are the most common dopamine agonists used. There are wide clinical variations among the trials in the starting time (from the day of human chorionic gonadotrophin (hCG) to the day following oocyte retrieval) ; the duration of the treatment (4-21 days), the dose of cabergoline (0.5 mg or 0.25 mg orally) and in the regimens used. At present, the best known effective regimen is 0.5 mg of cabergoline for 8 days or rectal bromocriptine at a daily dose of 2.5 mg for 16 days. Dopamine agonists have shown significant evidences of their efficacy in the prevention of moderate and early-onset OHSS (9.41%), compared with a placebo (21.45%), which cannot be confirmed for the treatment of late OHSS. It would be advisable to start with the treatment on the day of hCG injection or preferably a few hours earlier. The use of dopamine agonists should be indicated in patients at high risk of OHSS, as well as in patients with a history of previous OHSS even without evident signs of the syndrome. |
| تدمد: | 1473-0766 0951-3590 |
| DOI: | 10.3109/09513590.2014.943716 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2364194223823297e7d735e4db6ee905 https://doi.org/10.3109/09513590.2014.943716 |
| Rights: | CLOSED |
| رقم الانضمام: | edsair.doi.dedup.....2364194223823297e7d735e4db6ee905 |
| قاعدة البيانات: | OpenAIRE |
| ResultId |
1 |
|---|---|
| Header |
edsair OpenAIRE edsair.doi.dedup.....2364194223823297e7d735e4db6ee905 807 3 unknown 806.611938476563 |
| PLink |
https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....2364194223823297e7d735e4db6ee905&custid=s6537998&authtype=sso |
| FullText |
Array
(
[Availability] => 0
)
Array ( [0] => Array ( [Url] => https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2364194223823297e7d735e4db6ee905# [Name] => EDS - OpenAIRE [Category] => fullText [Text] => View record in OpenAIRE [MouseOverText] => View record in OpenAIRE ) ) |
| Items |
Array
(
[Name] => Title
[Label] => Title
[Group] => Ti
[Data] => Dopamine agonists in prevention of ovarian hyperstimulation syndrome
)
Array ( [Name] => Author [Label] => Authors [Group] => Au [Data] => <searchLink fieldCode="AR" term="%22Patrik+Stanić%22">Patrik Stanić</searchLink><br /><searchLink fieldCode="AR" term="%22Slavko+Orešković%22">Slavko Orešković</searchLink><br /><searchLink fieldCode="AR" term="%22Lidija+Beketić-Orešković%22">Lidija Beketić-Orešković</searchLink><br /><searchLink fieldCode="AR" term="%22Miro+Kasum%22">Miro Kasum</searchLink><br /><searchLink fieldCode="AR" term="%22Davor+Ježek%22">Davor Ježek</searchLink><br /><searchLink fieldCode="AR" term="%22Hrvoje+Vrcic%22">Hrvoje Vrcic</searchLink><br /><searchLink fieldCode="AR" term="%22Marijeta+Pekez%22">Marijeta Pekez</searchLink> ) Array ( [Name] => TitleSource [Label] => Source [Group] => Src [Data] => <i>Gynecological Endocrinology</i>. 30:845-849 ) Array ( [Name] => Publisher [Label] => Publisher Information [Group] => PubInfo [Data] => Informa UK Limited, 2014. ) Array ( [Name] => DatePubCY [Label] => Publication Year [Group] => Date [Data] => 2014 ) Array ( [Name] => Subject [Label] => Subject Terms [Group] => Su [Data] => <searchLink fieldCode="DE" term="%22medicine%2Emedical%5Fspecialty%22">medicine.medical_specialty</searchLink><br /><searchLink fieldCode="DE" term="%22Cabergoline%22">Cabergoline</searchLink><br /><searchLink fieldCode="DE" term="%22Dopamine+agonist%22">Dopamine agonist</searchLink><br /><searchLink fieldCode="DE" term="%22ovarian+hyperstimulation+syndrome%22">ovarian hyperstimulation syndrome</searchLink><br /><searchLink fieldCode="DE" term="%22prevention%22">prevention</searchLink><br /><searchLink fieldCode="DE" term="%22Endocrinology%2C+Diabetes+and+Metabolism%22">Endocrinology, Diabetes and Metabolism</searchLink><br /><searchLink fieldCode="DE" term="%22Ovarian+hyperstimulation+syndrome%22">Ovarian hyperstimulation syndrome</searchLink><br /><searchLink fieldCode="DE" term="%22Placebo%22">Placebo</searchLink><br /><searchLink fieldCode="DE" term="%22Ovarian+Hyperstimulation+Syndrome%22">Ovarian Hyperstimulation Syndrome</searchLink><br /><searchLink fieldCode="DE" term="%22Endocrinology%22">Endocrinology</searchLink><br /><searchLink fieldCode="DE" term="%22Ovulation+Induction%22">Ovulation Induction</searchLink><br /><searchLink fieldCode="DE" term="%22Dopamine%22">Dopamine</searchLink><br /><searchLink fieldCode="DE" term="%22Internal+medicine%22">Internal medicine</searchLink><br /><searchLink fieldCode="DE" term="%22medicine%22">medicine</searchLink><br /><searchLink fieldCode="DE" term="%22Humans%22">Humans</searchLink><br /><searchLink fieldCode="DE" term="%22Ergolines%22">Ergolines</searchLink><br /><searchLink fieldCode="DE" term="%22Bromocriptine%22">Bromocriptine</searchLink><br /><searchLink fieldCode="DE" term="%22business%2Eindustry%22">business.industry</searchLink><br /><searchLink fieldCode="DE" term="%22Quinagolide%22">Quinagolide</searchLink><br /><searchLink fieldCode="DE" term="%22Obstetrics+and+Gynecology%22">Obstetrics and Gynecology</searchLink><br /><searchLink fieldCode="DE" term="%22medicine%2Edisease%22">medicine.disease</searchLink><br /><searchLink fieldCode="DE" term="%22Regimen%22">Regimen</searchLink><br /><searchLink fieldCode="DE" term="%22Dopamine+Agonists%22">Dopamine Agonists</searchLink><br /><searchLink fieldCode="DE" term="%22Aminoquinolines%22">Aminoquinolines</searchLink><br /><searchLink fieldCode="DE" term="%22Female%22">Female</searchLink><br /><searchLink fieldCode="DE" term="%22business%22">business</searchLink><br /><searchLink fieldCode="DE" term="%22medicine%2Edrug%22">medicine.drug</searchLink> ) Array ( [Name] => Abstract [Label] => Description [Group] => Ab [Data] => The aim of this review is to analyze the efficacy of different dopamine agonists in the prevention of ovarian hyperstimulation syndrome (OHSS). Cabergoline, quinagolide and bromocriptine are the most common dopamine agonists used. There are wide clinical variations among the trials in the starting time (from the day of human chorionic gonadotrophin (hCG) to the day following oocyte retrieval) ; the duration of the treatment (4-21 days), the dose of cabergoline (0.5 mg or 0.25 mg orally) and in the regimens used. At present, the best known effective regimen is 0.5 mg of cabergoline for 8 days or rectal bromocriptine at a daily dose of 2.5 mg for 16 days. Dopamine agonists have shown significant evidences of their efficacy in the prevention of moderate and early-onset OHSS (9.41%), compared with a placebo (21.45%), which cannot be confirmed for the treatment of late OHSS. It would be advisable to start with the treatment on the day of hCG injection or preferably a few hours earlier. The use of dopamine agonists should be indicated in patients at high risk of OHSS, as well as in patients with a history of previous OHSS even without evident signs of the syndrome. ) Array ( [Name] => ISSN [Label] => ISSN [Group] => ISSN [Data] => 1473-0766<br />0951-3590 ) Array ( [Name] => DOI [Label] => DOI [Group] => ID [Data] => 10.3109/09513590.2014.943716 ) Array ( [Name] => URL [Label] => Access URL [Group] => URL [Data] => <link linkTarget="URL" linkTerm="https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2364194223823297e7d735e4db6ee905" linkWindow="_blank">https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2364194223823297e7d735e4db6ee905</link><br /><link linkTarget="URL" linkTerm="https://doi.org/10.3109/09513590.2014.943716" linkWindow="_blank">https://doi.org/10.3109/09513590.2014.943716</link> ) Array ( [Name] => Copyright [Label] => Rights [Group] => Cpyrght [Data] => CLOSED ) Array ( [Name] => AN [Label] => Accession Number [Group] => ID [Data] => edsair.doi.dedup.....2364194223823297e7d735e4db6ee905 ) |
| RecordInfo |
Array
(
[BibEntity] => Array
(
[Identifiers] => Array
(
[0] => Array
(
[Type] => doi
[Value] => 10.3109/09513590.2014.943716
)
)
[Languages] => Array
(
[0] => Array
(
[Text] => Undetermined
)
)
[PhysicalDescription] => Array
(
[Pagination] => Array
(
[PageCount] => 5
[StartPage] => 845
)
)
[Subjects] => Array
(
[0] => Array
(
[SubjectFull] => medicine.medical_specialty
[Type] => general
)
[1] => Array
(
[SubjectFull] => Cabergoline
[Type] => general
)
[2] => Array
(
[SubjectFull] => Dopamine agonist
[Type] => general
)
[3] => Array
(
[SubjectFull] => ovarian hyperstimulation syndrome
[Type] => general
)
[4] => Array
(
[SubjectFull] => prevention
[Type] => general
)
[5] => Array
(
[SubjectFull] => Endocrinology, Diabetes and Metabolism
[Type] => general
)
[6] => Array
(
[SubjectFull] => Ovarian hyperstimulation syndrome
[Type] => general
)
[7] => Array
(
[SubjectFull] => Placebo
[Type] => general
)
[8] => Array
(
[SubjectFull] => Ovarian Hyperstimulation Syndrome
[Type] => general
)
[9] => Array
(
[SubjectFull] => Endocrinology
[Type] => general
)
[10] => Array
(
[SubjectFull] => Ovulation Induction
[Type] => general
)
[11] => Array
(
[SubjectFull] => Dopamine
[Type] => general
)
[12] => Array
(
[SubjectFull] => Internal medicine
[Type] => general
)
[13] => Array
(
[SubjectFull] => medicine
[Type] => general
)
[14] => Array
(
[SubjectFull] => Humans
[Type] => general
)
[15] => Array
(
[SubjectFull] => Ergolines
[Type] => general
)
[16] => Array
(
[SubjectFull] => Bromocriptine
[Type] => general
)
[17] => Array
(
[SubjectFull] => business.industry
[Type] => general
)
[18] => Array
(
[SubjectFull] => Quinagolide
[Type] => general
)
[19] => Array
(
[SubjectFull] => Obstetrics and Gynecology
[Type] => general
)
[20] => Array
(
[SubjectFull] => medicine.disease
[Type] => general
)
[21] => Array
(
[SubjectFull] => Regimen
[Type] => general
)
[22] => Array
(
[SubjectFull] => Dopamine Agonists
[Type] => general
)
[23] => Array
(
[SubjectFull] => Aminoquinolines
[Type] => general
)
[24] => Array
(
[SubjectFull] => Female
[Type] => general
)
[25] => Array
(
[SubjectFull] => business
[Type] => general
)
[26] => Array
(
[SubjectFull] => medicine.drug
[Type] => general
)
)
[Titles] => Array
(
[0] => Array
(
[TitleFull] => Dopamine agonists in prevention of ovarian hyperstimulation syndrome
[Type] => main
)
)
)
[BibRelationships] => Array
(
[HasContributorRelationships] => Array
(
[0] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Patrik Stanić
)
)
)
[1] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Slavko Orešković
)
)
)
[2] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Lidija Beketić-Orešković
)
)
)
[3] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Miro Kasum
)
)
)
[4] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Davor Ježek
)
)
)
[5] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Hrvoje Vrcic
)
)
)
[6] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Marijeta Pekez
)
)
)
)
[IsPartOfRelationships] => Array
(
[0] => Array
(
[BibEntity] => Array
(
[Dates] => Array
(
[0] => Array
(
[D] => 05
[M] => 08
[Type] => published
[Y] => 2014
)
)
[Identifiers] => Array
(
[0] => Array
(
[Type] => issn-print
[Value] => 14730766
)
[1] => Array
(
[Type] => issn-print
[Value] => 09513590
)
[2] => Array
(
[Type] => issn-locals
[Value] => edsair
)
)
[Numbering] => Array
(
[0] => Array
(
[Type] => volume
[Value] => 30
)
)
[Titles] => Array
(
[0] => Array
(
[TitleFull] => Gynecological Endocrinology
[Type] => main
)
)
)
)
)
)
)
|
| IllustrationInfo |